BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
FRA:BSX • US1011371077
64 EUR
-0.8 (-1.23%)
Last: Feb 20, 2026, 07:00 PM
Overall BSX gets a fundamental rating of 5 out of 10. We evaluated BSX against 67 industry peers in the Health Care Equipment & Supplies industry. While BSX has a great profitability rating, there are some minor concerns on its financial health. BSX is valued quite expensive, but it does show an excellent growth. These ratings would make BSX suitable for growth investing!
1. Profitability
1.1 Basic Checks
- BSX had positive earnings in the past year.
- BSX had a positive operating cash flow in the past year.
- BSX had positive earnings in each of the past 5 years.
- Of the past 5 years BSX 4 years had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 6.54%, BSX is in the better half of the industry, outperforming 74.63% of the companies in the same industry.
- BSX has a better Return On Equity (11.93%) than 71.64% of its industry peers.
- With a decent Return On Invested Capital value of 8.35%, BSX is doing good in the industry, outperforming 67.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROIC | 8.35% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BSX has a Profit Margin of 14.42%. This is amongst the best in the industry. BSX outperforms 83.58% of its industry peers.
- BSX's Profit Margin has improved in the last couple of years.
- BSX has a Operating Margin of 19.40%. This is amongst the best in the industry. BSX outperforms 80.60% of its industry peers.
- In the last couple of years the Operating Margin of BSX has grown nicely.
- The Gross Margin of BSX (68.57%) is better than 76.12% of its industry peers.
- BSX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% |
OM growth 3Y6.45%
OM growth 5Y16.7%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y-0.1%
GM growth 5Y1.06%
2. Health
2.1 Basic Checks
- BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- There is no outstanding debt for BSX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- BSX has an Altman-Z score of 4.49. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of BSX (4.49) is better than 76.12% of its industry peers.
- The Debt to FCF ratio of BSX is 3.03, which is a good value as it means it would take BSX, 3.03 years of fcf income to pay off all of its debts.
- BSX's Debt to FCF ratio of 3.03 is fine compared to the rest of the industry. BSX outperforms 71.64% of its industry peers.
- BSX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
- BSX has a Debt to Equity ratio (0.48) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 4.49 |
ROIC/WACC0.86
WACC9.71%
2.3 Liquidity
- A Current Ratio of 1.51 indicates that BSX should not have too much problems paying its short term obligations.
- BSX's Current ratio of 1.51 is in line compared to the rest of the industry. BSX outperforms 44.78% of its industry peers.
- A Quick Ratio of 0.96 indicates that BSX may have some problems paying its short term obligations.
- With a Quick ratio value of 0.96, BSX is not doing good in the industry: 62.69% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 21.51% over the past year.
- The Earnings Per Share has been growing by 26.01% on average over the past years. This is a very strong growth
- Looking at the last year, BSX shows a quite strong growth in Revenue. The Revenue has grown by 19.88% in the last year.
- BSX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.16% yearly.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
3.2 Future
- The Earnings Per Share is expected to grow by 13.13% on average over the next years. This is quite good.
- Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 10.46% on average per year.
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.13%
Revenue Next Year11.42%
Revenue Next 2Y11.15%
Revenue Next 3Y10.54%
Revenue Next 5Y10.46%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 24.62 indicates a rather expensive valuation of BSX.
- The rest of the industry has a similar Price/Earnings ratio as BSX.
- When comparing the Price/Earnings ratio of BSX to the average of the S&P500 Index (26.99), we can say BSX is valued inline with the index average.
- A Price/Forward Earnings ratio of 21.48 indicates a rather expensive valuation of BSX.
- BSX's Price/Forward Earnings ratio is in line with the industry average.
- BSX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.62 | ||
| Fwd PE | 21.48 |
4.2 Price Multiples
- 67.16% of the companies in the same industry are cheaper than BSX, based on the Enterprise Value to EBITDA ratio.
- BSX's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.18 | ||
| EV/EBITDA | 24.15 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The decent profitability rating of BSX may justify a higher PE ratio.
- BSX's earnings are expected to grow with 13.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.66
PEG (5Y)0.95
EPS Next 2Y14.13%
EPS Next 3Y13.68%
5. Dividend
5.1 Amount
- BSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:BSX (2/20/2026, 7:00:00 PM)
64
-0.8 (-1.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04 2026-02-04/bmo
Earnings (Next)04-21 2026-04-21/bmo
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap94.91B
Revenue(TTM)20.07B
Net Income(TTM)2.79B
Analysts86
Price Target107.92 (68.63%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-1.07%
PT rev (3m)-2.37%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)0.01%
EPS NY rev (3m)0.12%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)0.04%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.62 | ||
| Fwd PE | 21.48 | ||
| P/S | 5.76 | ||
| P/FCF | 29.18 | ||
| P/OCF | 24.12 | ||
| P/B | 4.77 | ||
| P/tB | N/A | ||
| EV/EBITDA | 24.15 |
EPS(TTM)2.6
EY4.06%
EPS(NY)2.98
Fwd EY4.66%
FCF(TTM)2.19
FCFY3.43%
OCF(TTM)2.65
OCFY4.15%
SpS11.1
BVpS13.42
TBVpS-1.14
PEG (NY)1.66
PEG (5Y)0.95
Graham Number28.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROCE | 10.04% | ||
| ROIC | 8.35% | ||
| ROICexc | 8.65% | ||
| ROICexgc | 29.1% | ||
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% | ||
| FCFM | 19.76% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5Y16.7%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y-0.1%
GM growth 5Y1.06%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.18 | ||
| Cap/Depr | 59.36% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.6% | ||
| Profit Quality | 136.98% | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 4.49 |
F-Score6
WACC9.71%
ROIC/WACC0.86
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.13%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
Revenue Next Year11.42%
Revenue Next 2Y11.15%
Revenue Next 3Y10.54%
Revenue Next 5Y10.46%
EBIT growth 1Y30.66%
EBIT growth 3Y24.06%
EBIT growth 5Y34.39%
EBIT Next Year25.02%
EBIT Next 3Y15.69%
EBIT Next 5Y14.81%
FCF growth 1Y77.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.53%
OCF growth 3YN/A
OCF growth 5YN/A
BOSTON SCIENTIFIC CORP / BSX.DE FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE.
What is the valuation status for BSX stock?
ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Overvalued.
How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?
BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 7 / 10.
What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 24.62 and the Price/Book (PB) ratio is 4.77.
Can you provide the expected EPS growth for BSX stock?
The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 14.83% in the next year.